A phase 2 clinical trial demonstrates that #retatrutide, a triple agonist of the GIP, GLP-1, and glucagon receptors, results in up to 82% reduction in liver fat #MASLD @ArunJSanyalVCU A phase 2 clinical trial demonstrates that #retatrutide, a triple agonist of the GIP, GLP-1, and glucagon receptors, results in up to 82% reduction in liver fat #MASLD @ArunJSanyalVCU Join the conversation
While BPC-157 itself is cleared from the body within hours, its healing effects can last significantly longer often days or weeksthanks to the powerful biological processes it triggers
Keeping track of your blood sugar levels, weight changes, and any side effects can help your healthcare provider adjust the dose if necessary
This can reduce how quickly we burn in the sun
Working With Canadian Physicians Canadian physicians vary widely in their familiarity with obesity pharmacotherapy